ArticleJournal of materials science. Materials in medicine2025
Sustained intraocular pressure-lowering effect and biocompatibility of a single subconjunctival administration of hydrogel-encapsulated nano-brinzolamide.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Brinzolamide is a widely used treatment for glaucoma, but its effectiveness relies on at least twice-daily dosing, which can be challenging for patient adherence. To overcome this limitation, we developed an injectable hydrogel-based delivery system designed to maintain therapeutic drug levels with a single administration. This approach aims to simplify treatment and improve clinical outcomes. Brinzolamide-loaded polyethylene glycol poly (lactic-co-glycolic acid) (PEG-PLGA) nanoparticles were encapsulated within a hydrogel synthesized through the crosslinking of oxidized hyaluronic acid (OHA) and carboxymethyl chitosan (CMC). In vitro studies were conducted to assess the nanoparticles' characterization, release profile, and biocompatibility. In a steroid-induced high intraocular pressure (IOP) mouse model, the efficacy of a single subconjunctival injection in lowering IOP was evaluated. Additionally, both cellular and animal biocompatibility were assessed. The brinzolamide-loaded hydrogel system (Hydrogel@Brz) contained nanoparticles with an average diameter of 40.76 nm, exhibiting a stable size distribution and a spherical morphology. The hydrogel demonstrated excellent injectability, self-healing properties, and a porous structure conducive to nanoparticle encapsulation. In vitro release studies revealed a sustained drug release of 86% over 14 days. No cytotoxicity was observed in human primary trabecular meshwork cells (HTMCs), human Tenon's capsule fibroblasts (HTFs), or the retinal ganglion cell line R28. In vivo, a single injection led to a prolonged IOP reduction lasting up to 21 days. No signs of drug toxicity were detected in ocular tissue sections, transverse optic nerve sections under transmission electron microscopy, or pathology slides of various organs. The brinzolamide-loaded hydrogel has demonstrated promising potential for sustained drug delivery and effective intraocular pressure reduction while maintaining good biocompatibility. However, further studies in larger animal models and long-term evaluations are needed to confirm its clinical applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.